Cross-Talk of the CNS With Immune Cells and Functions in Health and Disease

by Agata Matejuk, Arthur A. Vandenbark, Arthur A. Vandenbark, Arthur A. Vandenbark, Halina Offner, Halina Offner, Halina Offner
Published 2021-05-01

A novel neurotherapeutic for multiple sclerosis, ischemic injury, methamphetamine addiction, and traumatic brain injury

by Arthur A. Vandenbark, Roberto Meza-Romero, Gil Benedek, Halina Offner
Published 2019-01-01

Partial MHC/neuroantigen peptide constructs: a potential neuroimmune-based treatment for methamphetamine addiction.

by Jennifer M Loftis, Clare J Wilhelm, Arthur A Vandenbark, Marilyn Huckans
Published 2013-01-01

Targeting immune co-stimulatory effects of PD-L1 and PD-L2 might represent an effective therapeutic strategy in stroke

by Sheetal eBodhankar, Sheetal eBodhankar, Yingxin eChen, Andrew eLapato, Andrew eLapato, Arthur A. Vandenbark, Arthur A. Vandenbark, Arthur A. Vandenbark, Stephanie J Murphy, Stephanie J Murphy, HALINA eOFFNER, HALINA eOFFNER, HALINA eOFFNER
Published 2014-08-01

Estrogen-induced compensatory mechanisms protect IL-10-deficient mice from developing EAE

by Hilary A. Seifert, Grant Gerstner, Gail Kent, Arthur A. Vandenbark, Halina Offner
Published 2019-10-01

RTL551 treatment of EAE reduces CD226 and T-bet+ CD4 T cells in periphery and prevents infiltration of T-bet+ IL-17, IFN-γ producing T cells into CNS.

by Sushmita Sinha, Lisa M Miller, Sandhya Subramanian, Gregory G Burrows, Arthur A Vandenbark, Halina Offner
Published 2011-01-01

Major histocompatibility complex Class II-based therapy for stroke

by Bella M Gonzales-Portillo, Jea-Young Lee, Arthur A Vandenbark, Halina Offner, Cesario V Borlongan
Published 2021-01-01

Sex-dependent treatment of chronic EAE with partial MHC class II constructs

by Gil Benedek, Priya Chaudhary, Roberto Meza-Romero, Evan Calkins, Gail Kent, Halina Offner, Dennis Bourdette, Arthur A. Vandenbark
Published 2017-05-01

Recombinant T-Cell Receptor Ligand (RTL) for Treatment of Multiple Sclerosis: A Double-Blind, Placebo-Controlled, Phase 1, Dose-Escalation Study

by Vijayshree Yadav, Dennis N. Bourdette, James D. Bowen, Sharon G. Lynch, David Mattson, Jana Preiningerova, Christopher T. Bever, Jack Simon, Andrew Goldstein, Gregory G. Burrows, Halina Offner, Al J. Ferro, Arthur A. Vandenbark
Published 2012-01-01